

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 21417-91482

SERIAL No.: 09/723,307

APPLICANT: CALENOFF et al.

INFORMATION DISCLOSURE STATEMENT


FILING DATE Nov. 27, 2000

GROUP: Unknown
1631

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
12	AA	4,399,216	Aug. 16, 1983	Axel, et al.			
	AB	4,585,742	Apr. 29, 1986	Bernal			
	AC	5,194,254	Mar. 16, 1993	Barber, et al.			
	AD	5,342,774	Aug. 30, 1994	Boon, et al.			
	AE	5,593,972	Jan. 14, 1997	Weiner, et al.			
	AF	5,616,477	Apr. 1, 1997	Price			
	AG	5,620,955	Apr. 15, 1997	Knight, et al.			
	AH	5,736,517	Apr. 7, 1998	Bogden, et al.			
	AI	5,750,110	May 12, 1998	Prieels, et al.			
	AJ	5,763,164	June 9, 1998	Calenoff			
	AK	5,770,721	June 23, 1998	Ershov, et al.			
	AL	5,772,997	June 30, 1998	Hudziak, et al.			
	AM	5,817,637	Oct. 6, 1998	Weiner, et al.			
	AN	5,830,876	Nov. 3, 1998	Weiner, et al.			
	AO	5,837,251	Nov. 17, 1998	Srivastava			
	AP	5,851,756	Dec. 22, 1998	Steinman, et al.			
	AQ	5,861,247	Jan. 19, 1999	Mirzabekov, et al.			
	AR	5,871,756	Feb. 16, 1999	Jeffcoat, et al.			
	AS	5,876,735	Mar. 2, 1999	Reed			
	AT	5,876,966	Mar. 2, 1999	Reed			
	AU	5,942,235	Aug. 24, 1999	Paoletti			
	AV	5,962,320	Oct. 5, 1999	Robinson			
	AW	5,981,505	Nov. 9, 1999	Weiner, et al.			
	AX	5,981,706	Nov. 9, 1999	Wallen, et al.			
	AY	5,985,270	Nov. 16, 1999	Srivastava			
	AZ	5,997,873	Dec. 7, 1999	Srivastava			
	BA	6,013,268	Jan. 11, 2000	Reed			
	BB	6,030,618	Feb. 29, 2000	Srivastava			
	BC	6,051,237	Apr. 18, 2000	Paterson			
	BD	6,063,384	May 16, 2000	Morrow, et al.			
	BE	6,077,663	June 20, 2000	Curiel, et al.			
	BF	6,080,399	June 27, 2000	Gajewski, et al.			
	BG	6,080,409	June 27, 2000	Laus, et al.			
	BH	6,106,829	Aug. 22, 2000	He, et al.			
	BI	6,136,315	Oct. 24, 2000	Srivastava			

Shubzon 11/11/03



APR 10 2001

PATENT & TRADEMARK OFFICE

Document Number	Date	Country	Class	Subclass	Translation Yes No
BJ					
BK					

INTERNATIONAL SEARCH REPORT

BL					
BM					
BN					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

BO	BARRATT-BOYES, S.M., et al. (1998) "Chimpanzee Dendritic Cells Derived In Vitro from Blood Monocytes and Pulsed with Antigen Elicit Specific Immune Responses In Vivo." Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation. <i>J. Immunother.</i> 21(2): 142-148.
BP	BEGUM, N.A. et al. (1995) "Differential Display and Integrin Alpha 6 Messenger RNA Overexpression in Hepatocellular Carcinoma." <i>Hepatology.</i> 22(5): 1447-1455.
BQ	BONKHOF, H. (1998) "Analytical Molecular Pathology of Epithelial-Stromal Interactions in the Normal and Neoplastic Prostate." <i>Anal. Quant. Cytol. Histo.</i> 20(5): 437-442.
BP	BRAME, C.J. et al. (1999) "Identification of Extremely Reactive γ -Ketoaldehydes (Isolevuglandins) as Products of the Isoprostane Pathway and Characterization of Their Lysyl Protein Adducts." <i>J. Biol. Chem.</i> 274(19): 13139-13146.
BS	BRYDEN, A.A.G., et al. (1999) "Paradoxical Expression of E-Cadherin in Prostatic Bone Metastases." <i>BJU Int.</i> 84(9): 1032-1034.
BT	CHEEVER, M.A., et al. (1997) "Therapy with Cultured T Cells: Principles Revisited." <i>Immunol. Rev.</i> 157: 177-194.
BU	CRESS, A.E., et al. (1995) "The $\alpha 6 \beta 1$ and $\alpha 6 \beta 4$ Integrins in Human Prostate Cancer Progression." <i>Cancer Metastasis Revs.</i> 14(3): 219-228.
BV	DAMIANO, J.S. et al. (1999) "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines." <i>Blood</i> 93(5): 1658-1667.
BW	DAMJANOVICH, L. et al. (1997) "Integrin Expression on Normal and Neoplastic Human Breast Epithelium." <i>Acta Chir. Hung.</i> 36(1-4): 69-71.
BX	DISIS, M.L. et al. (1999) "Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer using a Peptide-based Vaccine." <i>Clin. Cancer Res.</i> 5(6): 1289-1297.
BP	DISIS, M.L., et al. (1997) "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer." <i>Advances in Cancer Research</i> 344-370.
BP	DISIS, M.L. et al. (1998) "HER-2/neu Oncogenic Protein: Issues in Vaccine Development." <i>Crit. Revs. Immunol.</i> 18(1-2): 37-45.
CA	DISIS, M.L. et al. (1998) "Human HER-2/neu Protein Immunization Circumvents Tolerance to Rat neu: A Vaccine Strategy for "Self" Tumour Antigens." <i>Immunology</i> 93(2): 192-199.
CB	DONG, J-T., et al. (1996) "Down-Regulation of the KAI1 Metastasis Suppressor Gene during the Progression of Human Prostatic Cancer Infrequently Involves Gene Mutation or Allelic Loss." <i>Cancer Res.</i> 56(19): 4387-4390.
CC	EKBLOM, M., et al. (1998) "Laminin Isoforms and Epithelial Development." <i>Ann. N.Y. Acad. Sci.</i> 857: 194-211.
CD	FAUCHÈRE, J.L. et al. (1983) "Hydrophobic Parameters II of Amino-Acid Side Chains from the Partitioning of N-Acetyl-Amino-Acid Amides." <i>Eur. J. Med. Chem.</i> 18(4): 369-375.
CF	FLEISCHMAJER, R. et al. (1998) "There is Binding of Collagen IV to $\beta 1$ Integrin during Early Skin Basement Membrane Assembly." <i>Ann. N.Y. Acad. Sci.</i> 857: 212-227.
CF	FRAGA, S., et al. (1990) "Prediction of the Secondary Structure and Functional Sites of Major Histocompatibility Complex Molecules." <i>J. Mol. Recognit.</i> 3(2): 65-73.
CG	FRIEDL, P., et al. (1998) "Integrins, Cell Matrix Interactions and Cell Migration Strategies: Fundamental Differences in Leukocytes and Tumor Cells." <i>Cell Adhes. Commun.</i> 6(2-3): 225-236.

Shubozhou

1/11/03

APR 10 2001

CH	FUDGE, K., et al. (1994) "Immunohistochemistry Analysis of Platelet-derived Growth Factor A and B Chains and Platelet-derived Growth Factor α and β Receptor Expression in Benign Prostatic Hyperplasias and Gleason-graded Human Prostate Adenocarcinomas." <i>Mod. Pathol.</i> 7(5): 549-554.
CI	FUJIWARA, H. (1998) "Physiological Roles of Integrin $\alpha_v\beta_1$ in Ovarian Functions." <i>Horm. Res.</i> 50(2): 25-29.
CJ	FURUKAWA, F., et al. (1994) "Cadherins in Cutaneous Biology." <i>J. Dermatol.</i> 21(11): 802-813.
CK	GILEWSKI, T., et al. (2000) "Vaccination of High-Risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21." <i>Clin. Cancer Res.</i> 6(5): 1693-1701.
CL	GIRI, D., et al. (1999) "Alterations in Expression of Basic Fibroblast Growth Factor (FGF) 2 and its Receptor FGFR-1 in Human Prostate Cancer." <i>Clin. Cancer Res.</i> 5(5): 1063-1071.
CM	GOLDENBERG, D.M. (1993) "Monoclonal Antibodies in Cancer Detection and Therapy." <i>Am. J. Med.</i> 94(3): 297-312.
CN	GRASSO, A.W., et al. (1997) "ErbB Kinases and NDF Signaling in Human Prostate Cancer Cells." <i>Oncogene</i> 15(22): 2705-2716.
CO	HENDERSON, R.A., et al. (1998) "Retroviral Expression of MUC-1 Human Tumor Antigen with Intact Repeat Structure and Capacity to Elicit Immunity In Vivo." Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer. Tumor Antigens Recognized by T Cells. <i>J. Immunother.</i> 21(4): 247-256.
CP	HOPP, T.P., et al. (1981) "Prediction of Protein Antigenic Determinants from Amino Acid Sequences." <i>Proc. Natl. Acad. Sci. USA.</i> 78(6): 3824-3828.
CQ	HUDZIAK, R.M., et al. (1989) "p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor." <i>Mol. Cell. Biol.</i> 9(3): 1165-1172.
CR	HUSSAIN, R., et al. (1996) "Structure-Function Correlation and Biostability of Antibody CDR-Derived Peptides as Tumour Imaging Agents." <i>Biomed. Pept. Proteins Nucleic Acids</i> 2(3): 67-70.
CS	KATSURA, M. et al. (1998) "Overexpression of CD44 Variants 6 and 7 in Human Endometrial Cancer." <i>Gynecol. Oncol.</i> 71(2): 185-189.
CT	KRAMER, G., et al. (1995) "High Expression of A CD38-Like Molecule in Normal Prostatic Epithelium and its Differential Loss in Benign and Malignant Disease." <i>J. Urol.</i> 154(5): 1636-1641.
CU	LIAPSIS, H., et al. (1996) "Integrin $\alpha_v\beta_3$ Expression by Bone-Residing Breast Cancer Metastases." <i>Diagn. Mol. Pathol.</i> 5(2): 127-135.
CV	LOHI, J., et al. (1998) "Neoexpression of the Epithelial Adhesion Complex Antigens in Thyroid Tumours is Associated with Proliferation and Squamous Differentiation Markers." <i>J. Pathol.</i> 184(2): 191-196.
CW	LUO, W., et al. (1999) "Tumor-suppressive Activity of CD66a in Prostate Cancer." <i>Cancer Gene Ther.</i> 6(4): 313-321.
CX	PARKER, J.M.R., et al. (1986) "New Hydrophilicity Scale Derived from High-Performance Liquid Chromatography Peptide Retention Data: Correlation of Predicted Surface Residues with Antigenicity and X-ray-Derived Accessible Sites." <i>Biochemistry</i> 25: 5425-5432.
CY	RABINOVITZ, I., et al. (1995) "Integrin α_6 Expression in Human Prostate Carcinoma Cells is Associated with a Migratory and Invasive Phenotype <i>in vitro</i> and <i>in vivo</i> ." <i>Clin. Exp. Metastasis</i> 13(6): 481-491.
CZ	ROKHLIN, O.W., et al. (1997) "Fas-mediated Apoptosis in Human Prostatic Carcinoma Cell Lines." <i>Cancer Res.</i> 57(9): 1758-1768.
DA	ROMANOV, V.I., et al. (1999) "RGD-Recognizing Integrins Mediate Interactions of Human Prostate Carcinoma Cells with Endothelial Cells In Vitro." <i>Prostate</i> 39(2): 108-118.
DB	RUOSLAHTI, E. (1997) "Integrins as Signaling Molecules and Targets for Tumor Therapy." <i>Kidney Int.</i> 51(5): 1413-1417.
DC	SHAMSI, F.A., et al. (1998) "Immunological Evidence for Methylglyoxal-derived Modifications <i>in Vivo</i> ." <i>J. of Biol. Chem.</i> 273(12): 6928-6936.
DD	SHAMSI, K., et al. (1998) "Superparamagnetic Iron Oxide Particles (SH U 555 A): Evaluation of Efficacy in Three Doses for Hepatic MR Imaging." <i>Radiology</i> 206(2): 365-371.
DE	SUZUKI, K. et al. (1999) "Reduced Substratum Adhesion and Decreased Expressions of β_1 and β_4 Integrins in Human Breast Cancer Cells with a Property of Anchorage-Independent Growth." <i>Int. J. Oncol.</i> 14(5): 897-904.
DF	TAKAHASHI, S., et al. (1998) "Relationship between CD44 Expression and Differentiation of Human Prostate Adenocarcinomas." <i>Cancer Letts.</i> 129(1): 97-102.
DG	TO, S.Y.C., et al. (1992) "Monoclonal Antibody-Coated Magnetite Particles as Contrast Agents for MR Imaging and Laser Therapy of Human Tumors." <i>J. Clin. Laser Med. Surg.</i> 10(3): 159-169.
DH	TOZAWA, K. (1996) "Activation of Nuclear Factor- κ B and Control of the Expression of Cell Adhesion Molecules in Human Prostate Cancer Cells." <i>Nippon Hinyokika Gakkai Zasshi</i> 87(9): 1082-1091.
DI	TRAN, N.L., et al. (1999) "N-Cadherin Expression in Human Prostate Carcinoma Cell Lines." <i>Am. J. Pathol.</i> 155(3): 787-798.

Shubhron 1/11/03

<i>h</i>	DJ	TSIMIKAS, S., <i>et al.</i> (1999) "Radiolabeled MDA2, an Oxidation-Specific, Monoclonal Antibody, Identifies Native Atherosclerotic Lesions in Vivo." <i>J. Nucl. Cardiol.</i> 6(1): 41-53.
<i>h</i>	DK	WATANABE, M., <i>et al.</i> (1999) "Progression-linked Overexpression of c-Met in Prostatic Intraepithelial Neoplasia and Latent as well as Clinical Prostate Cancers." <i>Cancer Letts.</i> 141(1-2): 173-178.
<i>h</i>	DL	ZHENG, Duo-Qi, <i>et al.</i> (1999) "Prostatic Carcinoma Cell Migration via $\alpha_5\beta_3$ Integrin Is Modulated by a Focal Adhesion Kinase Pathway ¹ ." <i>Cancer Res.</i> 59(7): 1655-1664.
Examiner <i>Shah</i>		Date Considered <i>1/11/03</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

BASED ON FORM PTO 1449

